Compare MUX & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | OGN |
|---|---|---|
| Founded | 1979 | 1923 |
| Country | Canada | United States |
| Employees | 1432 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | MUX | OGN |
|---|---|---|
| Price | $21.39 | $6.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $26.63 | $11.75 |
| AVG Volume (30 Days) | 988.1K | ★ 3.0M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | $22.52 | $0.42 |
| Revenue Next Year | $26.24 | $1.67 |
| P/E Ratio | ★ N/A | $8.31 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.38 | $5.69 |
| 52 Week High | $29.70 | $14.70 |
| Indicator | MUX | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 39.63 |
| Support Level | $17.91 | N/A |
| Resistance Level | $26.94 | $7.87 |
| Average True Range (ATR) | 1.23 | 0.24 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 52.12 | 51.79 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.